BACKGROUND: Certolizumab (CZP) is a pegylated anti-tumor necrosis factor (TNF) agent approved for the treatment of moderate-to-severe Crohn’s disease (CD). CZP therapy has proven effectiv...
1 Anne Marion Burnett School of Medicine, Fort Worth, Texas, United States;
2 Healix Infusion Therapy, LLC, Sugar Land, Texas, United States;
3 GI Alliance, United States;
4 Takeda Pharma...